Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07538804 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Jun 9, 2026 to Jul 10, 2026 Study sites: 4 to 5v3 Show 1 more changeShow less
    • Study sites: 4 to 5
  2. Recruitment opened Site details revised at 4 of 4 sitesv2 Show 1 more changeShow less
    • Site details revised at 4 of 4 sites
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a first-in-human (FIH) Phase I/II, multi-center, open-label, study of ANS02, in patients with advanced NSCLC. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS02 as monotherapy.
Trial Details
NCT Number NCT07538804
Lead Sponsor Avistone Biotechnology Co., Ltd.
Conditions Non-Small Cell Lung Cancer
Enrollment 294 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov